Future studies should examine the effect of imatinib on urothelial barrier function and downstream kinase targets (e.g., mTOR), to further elucidate the mechanism(s) by which imatinib improves urinary bladder function in CYP-induced cystitis. The gene discussed is MTOR; the disease is chronic cystitis.